Risk factors for clopidogrel resistance / 国际脑血管病杂志

ABSTRACT

Clopidogrel is the most commonly used antiplatelet agent for acute coronary syndrome, ischemic stroke, and before and after percutaneous coronary intervention, and endovascular treatment of large vessel occlusive stroke, but there are individual differences in antiplatelet effect, that is, clopidogrel resistance (CR). CR is usually attributed to the decrease of the concentration of sulfhydryl metabolites in plasma, and there are many factors that cause the decrease of the concentration of sulfhydryl metabolites. This article reviews the research progress of CR-related risk factors, so that clinicians can assess the risk of CR and adopt individualized antiplatelet therapy to improve the clinical outcome of patients.